Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Syngene International, a custom research organization and a subsidiary of Biocon Group, has announced that it will offer fully integrated drug discovery services by partnering with Sapient Discovery, a US-based biotechnology company.
Subscribe to our email newsletter
The companies intend to provide a highly integrated platform for structure-based drug discovery with one stop shop for structure-guided discovery, chemistry, biology and structural biology capabilities. This arrangement is said to be crucial at a time when cost-reductions and efficiency in the drug discovery process is driving companies to look for suitable outsourcing partners.
Kal Ramnarayan, president and CSO of Sapient Discovery, said: “Sapient Discovery’s proprietary Genes-to-Leads, Fragments-to-Leads and X-ray crystallography technologies provide dramatic reductions in the time and costs associated with compound synthesis and screening and expands the horizons of chemical diversity potentially applicable to novel or even well studied drug targets.”